ENZO BIOCHEM, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.13 USD | -1.74% |
|
-4.24% | -18.71% |
Financials (USD)
| Sales 2022 | 107M | Sales 2023 | 31.06M | Capitalization | 73.6M |
|---|---|---|---|---|---|
| Net income 2022 | -18M | Net income 2023 | 20M | EV / Sales 2022 | 1.07 x |
| Net cash position 2022 | 1.02M | Net cash position 2023 | 75.38M | EV / Sales 2023 | -0.06 x |
| P/E ratio 2022 |
-6.24
x | P/E ratio 2023 |
3.59
x | Employees | 185 |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 75.81% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 day | -1.74% | ||
| 1 week | -4.24% | ||
| Current month | -11.02% | ||
| 1 month | -9.60% | ||
| 3 months | -18.12% | ||
| 6 months | -18.12% | ||
| Current year | -18.71% |
1 week
1.07
1.20
1 month
1.071.30
Current year
1.071.50
1 year
1.072.74
3 years
1.004.15
5 years
1.004.85
10 years
1.0012.04
| Managers | Title | Age | Since |
|---|---|---|---|
Kara Cannon
CEO | Chief Executive Officer | 56 | 10-12-31 |
Elazar Rabbani
FOU | Founder | 81 | 76-07-31 |
Patricia Eckert
DFI | Director of Finance/CFO | 47 | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Steven Pully
CHM | Chairman | 64 | 23-10-25 |
Mary Tagliaferri
BRD | Director/Board Member | 58 | 20-11-16 |
Bradley Radoff
BRD | Director/Board Member | 51 | 22-01-02 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-18 | 1.13 | -1.74% | 203,077 |
| 24-04-17 | 1.15 | 0.00% | 123,985 |
| 24-04-16 | 1.15 | -0.86% | 54,912 |
| 24-04-15 | 1.16 | -0.85% | 117,279 |
| 24-04-12 | 1.17 | -0.85% | 103,259 |
Delayed Quote Nyse, April 18, 2024 at 04:00 pm EDT
More quotes
Enzo Biochem, Inc. is focused on molecular diagnostics and has a portfolio of technical platforms and reagent sets supporting a diverse range of biomedical research and translational science needs. The Company operates through the product segment, which manufactures, develops and markets products and tools for clinical research, translational research, drug development and bioscience research customers worldwide. The Company is engaged in product development and manufactures and supplies a comprehensive portfolio of products, including antibodies, genomic probes, assays, biochemicals and proteins. The Company's products and technologies are used in translational research and drug development areas, including cell biology, genomics, assays, immunohistochemistry and small molecule chemistry. Its life science division supports the work of research centers and industry partners. It has built a portfolio of intellectual property assets, comprised of around 457 owned patents worldwide.
Calendar
2024-06-09
- Q3 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| -18.71% | 58.91M | |
| -1.82% | 41.36B | |
| +44.25% | 41.3B | |
| +2.56% | 39.61B | |
| -12.11% | 25.62B | |
| +3.09% | 24.09B | |
| -24.16% | 18.38B | |
| +22.12% | 11.85B | |
| -3.74% | 11.82B | |
| +7.75% | 11.07B |
- Stock Market
- Equities
- ENZ Stock
